Back to top

Priovant Therapeutics announces FDA approval of Lisraya

Priovant Therapeutics announced that the U.S. FDA has approved Lisraya 30 mg for the treatment of adults with dermatomyositis. Lisraya is a pill ta...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Roivant Sciences Ltd. (ROIV)